In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Paul Royalty buys Dyax's phage rights for $30mm

Executive Summary

Dyax (therapeutic candidates for cancer and inflammation) has raised $30mm with the sale to Paul Capital Partners' Paul Royalty Fund of a tiered percentage of its revenues from its phage display licensing and funded research program (PDLFRP, which has already granted over 75 licenses) over the next 10 years. Dyax may also get an additional $5mm if the PDLFRP reaches certain predetermined revenue levels in the next 24 months. Dyax reserves the right to repurchase the rights at any time. The company will use the funds to continue the development of its hereditary angioedema and CABG programs and further the other drug candidates in its pipeline.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies

Advertisement
UsernamePublicRestriction

Register